BrigatinibBrigatinib, sold under the brand name Alunbrig among others, is a small-molecule targeted cancer therapy being developed by Ariad Pharmaceuticals, Inc. Brigatinib acts as an inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR), as well as several… Read from the Drugbox of the Wikipedia article Brigatinib, revision 1369611529.

Property

Value

Formula

C29H39ClN7O2P, 584.10 g/mol

The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.